ATXN2 and spinocerebellar ataxia type 2: Down-regulating ataxin-2 could help attenuate the toxicity of TDP-43 and may make ataxin-2 a potential therapeutic target in TDP-43-related disorders, in addition to its potential benefit in SCA2 (Watanabe et al., 2020).